All News
Landmark Study Investigating Novel Alzheimer’s Biomarkers Advances to Data Analysis Stage
Bio-Hermes won’t just change Alzheimer’s research and diagnostics. It has the potential to save and change lives. WASHINGTON, DC (June 14, 2023) — Up to 50 percent of people in the U.S. with Alzheimer’s receive an imprecise or inaccurate diagnosis of their cognitive condition. The tools typically used to detect the disease, like a PET […]
GAP President to FDA: Full Approval of Leqembi
Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 12) – “Last week, I was proud to participate in the open public hearing session at the Food and Drug Administration (FDA)’s Meeting of the Peripheral and Central Nervous System Drugs Advisory Committee Meeting in support of full approval of […]
A Letter to First Lady Rosalynn Carter
June 8, 2023 Mrs. Rosalynn Carter c/o The Carter Center 453 John Lewis Freedom Parkway NE Atlanta, GA 30307-1406 Dear Mrs. Carter: I read with heartfelt interest the news announcing your dementia diagnosis. Thank you for sharing this news so bravely and publicly. Receiving a dementia or Alzheimer’s diagnosis, and how that news impacts a […]
Medicare Outlines Plan to Expand Coverage for Costly New Alzheimer’s Drugs
GAP President John Dwyer was quoted in the Washington Post on the CMS decision. The Centers for Medicare and Medicaid Services said it would cover a class of Alzheimer’s drugs that includes Leqembi if the medicines get traditional approval by drug regulators. (Eisai/Reuters) Medicare officials outlined plans Thursday to broadly cover a new class of […]
GAP President John Dwyer on CMS Decision: Too Early to Celebrate
News that the U.S. Centers for Medicare and Medicaid Services (CMS) will provide broader coverage for Alzheimer’s treatments lacks specifics; unclear if rural and non-hospital based physicians can participate Statement attributed to John M. Dwyer, President of the Global Alzheimer’s Platform Foundation: (WASHINGTON, DC, JUNE 1) — “It’s too early to celebrate. The U.S. Centers […]
New Poll: Huge Majorities Want Medicare to Cover Cost of Alzheimer’s Drugs
Americans want Congress and the president to step in if CMS doesn’t change its restrictive coverage policy. WASHINGTON (May 23, 2023) — Nearly nine in ten voters favor (87% favor, 77% strongly favor) requiring Medicare to cover the cost of FDA-approved drugs that can slow the progression of Alzheimer’s disease, according to a new poll […]
Black, Hispanic volunteers sought for Alzheimer’s study in Albany
GAP-Net Site The Alzheimer’s Disease Research Center of Albany is looking for volunteers for their research studies. ALBANY — The Alzheimer’s Disease Research Center of Albany is looking for volunteers for an Alzheimer’s clinical study, putting an emphasis on the recruitment of people of color. While people from underrepresented communities — including those who are […]
Exploring Alzheimer’s and Personal Journeys
GAP President on Donanemab Trial Results: Alzheimer’s Patients and Their Doctors May Have Another Disease-Modifying Therapy to Address this Disease
WASHINGTON, DC, May 3, 2023 — Following the announcement of Eli Lilly’s Phase 3 results on a study evaluating donanemab for the treatment of Alzheimer’s disease, Global Alzheimer’s Platform Foundation® (GAP) President John Dwyer said, “Today’s announcement is good news. After waiting nearly 20 years for a new treatment for Alzheimer’s, Alzheimer’s patients and their doctors […]
House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage
House Energy & Commerce Subcommittee Tells CMS: Fix Alzheimer’s Drug Coverage WASHINGTON, DC (April 27, 2023) – The Global Alzheimer’s Platform Foundation®(GAP) President John Dwyer commends the strong, bipartisan leadership shown yesterday by U.S. Reps. Brett Guthrie (R-KY) and Anna Eshoo (D-CA) for admonishing the U.S. Centers for Medicare and Medicaid Services (CMS) administrator Chiquita […]